BVS - Bioventus Non-GAAP EPS of $0.10 misses by $0.06 revenue of $140.3M beats by $1.97M
- Bioventus press release ( NASDAQ: BVS ): Q2 Non-GAAP EPS of $0.10 misses by $0.06 .
- Revenue of $140.3M (+27.8% Y/Y) beats by $1.97M .
- FY Guidance: Net sales of $547.5 million to $562.5 million, representing year-over-year growth of approximately 27% to 31%, representing a tightening of the prior guidance of $545 million to $565 million leaving the mid-point unchanged; Adjusted EBITDA* of $94 million to $104 million, compared to $80.8 million for the year ended December 31, 2021, and representing an update from the prior guidance of $94 million to $107 million due to the inclusion of expenses related to CartiHeal; Non-GAAP EPS* of $0.47 to $0.57, compared to $0.75 for the year ended December 31, 2021. The Company is now providing Non-GAAP EPS guidance in light of the completion of the CartiHeal acquisition on July 12, 2022.
For further details see:
Bioventus Non-GAAP EPS of $0.10 misses by $0.06, revenue of $140.3M beats by $1.97M